This Month in JNM

Somatostatin receptor targeting: Maecke and Reubi review the development, current status, and future potential of diagnostic and therapeutic targeting of neuroendocrine tumors with radiolabeled probes.Page 841

Cell-level dosimetry and biologic response: Zanzonico looks at the challenges that nonuniformity poses for radionuclide dose–response and dose–toxicity predictions and previews a related article in this issue of JNM.Page 845

PET and incident PD dementia: Bohnen and colleagues describe a longitudinal study using ¹⁸F-FDG PET to assess early regional cerebral subcortical and cortical metabolic changes underlying incident dementia in individuals with Parkinson disease.Page 848

PET and antiangiogenic HGG treatment: Hutterer and colleagues compare MRI assessment with metabolic ¹⁸F-FET PET response evaluation during antiangiogenic treatment in patients with recurrent high-grade glioma.Page 856

Dual-time-point PET in brain tumors: Prieto and colleagues evaluate a method for dual-time-point ¹⁸F-FDG PET imaging for high-grade brain tumor detection and delineation using quantitative criteria applied on a voxel basis.Page 865

Myocardial perfusion reserve and revascularization: Slart and colleagues investigate whether myocardial perfusion reserve is related to survival in patients with ischemic heart disease after revascularization/viability assessment with gated ¹⁸F-FDG PET.Page 873

PET and tuberculosis in HIV: Sathekge and colleagues report on a pilot study of relationships between severity of tuberculosis as assessed by ¹⁸F-FDG PET at diagnosis and response to treatment in a group of patients with HIV.Page 880

Pancreatic uptake of ⁶⁸Ga-DOTANOC: Castellucci and colleagues assess the incidence of increased uptake of this somatostatin analog radiotracer in the head of the pancreas after serial PET/CT in a large population of patients with extrapancreatic neuroendocrine tumors.Page 886

⁹⁰Y-ibritumomab tiuxetan after ASCT: Ria and colleagues describe the results of this targeted radioimmunotherapy approach as consolidated therapy after autologous stem cell transplantation in patients with CD20-positive, aggressive non-Hodgkin lymphoma.Page 891

Long-term ¹³¹I-tositumomab results: Buchegger and colleagues provide an encouraging 10-y update on the safety and efficacy of this radioimmunotherapy in patients with relapsed or resistant indolent or transformed non-Hodgkin lymphoma.Page 896

Marrow visualization on kidney scans: Shapoval and colleagues look at the frequency of bone marrow visualization in ^99mTc-MAG3 renal scans and its association with various laboratory parameters.Page 901

Nuclear medicine in infancy: Treves and colleagues provide an educational overview of imaging in children younger than 1 y, including clinical indications, methods, patient handling/positioning, sedation, radiopharmaceutical dosages, instrumentation, and radiation exposures and risk.Page 905

Modeling response to lognormal uptake: Rajon and colleagues use a 3-dimensional model of cells in a heterogeneous carbon scaffold to assess the effects of nonuniformity of radioactivity among cells on dose response.Page 926

¹⁸F-PEG₆-IPQA PET: Tian and colleagues determine in nonhuman primates the pharmacokinetics, biodistribution, metabolism, and radiation dosimetry of this radiotracer created for factor receptor kinase–expressing non–small cell lung cancer xenografts.Page 934

DR5 PET tracer: Rossin and colleagues characterize the potential of ⁶⁴Cu-labeled conatumumab, a fully human monoclonal antibody that binds to and activates human death receptor 5, as a PET tracer for imaging DR5 in tumors.Page 942

Changes in P-gp function: Takashima and colleagues investigate developmental changes in P-glycoprotein function in the blood–brain barrier of nonhuman primates using PET with R-¹¹C-verapamil and ¹¹C-oseltamivir, with implications for drug response studies in children and adults.Page 950

Multimodal apoptosis imaging: Zhang and colleagues report on the development and evaluation of annexin A5-conjugated polymeric micelles for dual SPECT and optical fluorescence detection of apoptosis.Page 958

FBnTP after transient coronary occlusion: Higuchi and colleagues determine the stability of perfusion defect size over time and the magnitude of redistribution of this ¹⁸F-labeled myocardial perfusion PET agent in a rat model.Page 965

¹³¹I-N,N-dimethyltryptamine in the brain: Vitale and colleagues explore the relationship between this strong psychodysleptic drug and hallucinogenic processes through comparison with tryptamine in small-animal imaging, biodistribution, and pharmacokinetic studies.Page 970

Copolymer agent for hepatocyte imaging: Yang and colleagues synthesize and characterize galactose-carrying copolymers with hydrazinonicotinamide chains as bifunctional groups for ^99mTc-labeled SPECT targeting of specific hepatocytes.Page 978

PET and CXCR4 expression: De Silva and colleagues evaluate a positron-emitting monocyclam analog in subcutaneous brain tumors stably expressing this chemokine receptor and in colon tumors using dynamic and whole-body PET.Page 986

ABNM position statement: Frey and members of the American Board of Nuclear Medicine offer a definition of the scope of nuclear medicine practice and core professional competencies required now and for the future.Page 994

Report of ACR–SNM Task Force: Guiberteau and Graham report on the conclusions of a joint specialty effort to define current issues and develop recommendations for resident training in the rapidly evolving discipline of molecular imaging.Page 998

ON THE COVER

A study of the use of ⁶⁴Cu-AMD3465 as a PET imaging agent has shown it capable of detecting lesions in a CXCR4-dependent fashion with high tumor-to-muscle ratios. In the PET/CT images shown here, CXCR4 expression in subcutaneous U87 brain tumor xenografts is seen. This positron-emitting monocyclam analog may serve as a suitable scaffold for the synthesis of clinically translatable imaging agents.See page 989.

• © 2011 by Society of Nuclear Medicine